文献速递造血干细胞移植与细胞治疗血栓与止血

儿童造血干细胞移植中移植相关血栓性微血管病危险因素的新见解

New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT.
PubMed 文献 · Blood Adv · 2020-01-01

研究纳入2013至2016年间2家英国超区域中心439例儿童的474次造血干细胞移植,评估移植相关血栓性微血管病(TA-TMA)的危险因素。中位移植后153天,441例可评估病例中25例(5.6%)发生TA-TMA,无中心间差异。多因素分析显示活动性合并症、多次移植、急性移植物抗宿主病III-IV度为TA-TMA的显著危险因素。

要点

  • 441例可评估病例中25例(5.6%)发生TA-TMA,中位发生时间为移植后153天,无中心间差异。
  • 多因素分析显示活动性合并症、接受超过1次移植、aGVHD III-IV度为TA-TMA危险因素。
  • 以环孢素A/他克莫司为基础的GVHD预防不是TA-TMA的危险因素。

核心结论

  • 活动性合并症、后续移植和aGVHD III-IV度是TA-TMA的显著危险因素。
  • TA-TMA可能代表一种血管性GVHD,因此持续控制aGVHD对预防与GVHD相关的TA-TMA恶化很重要。

研究设计与样本

  • 2013年至2016年间,2家英国超区域中心共439例儿童接受474次造血干细胞移植。
  • 中位移植后153天评估TA-TMA发生情况,441例可评估。

主要发现

  • 441例可评估病例中25例(5.6%)发生TA-TMA,无中心间差异证据。
  • 供者类型为相合同胞/相合同家族供者 vs 相合无关供者 vs 不相合无关供者/单倍体移植时,TA-TMA发生率分别为1.8% vs 6.1% vs 8.3%,呈趋势。
  • 有活动性合并症者TA-TMA风险增加:13% vs 无合并症者3.7%。
  • 接受超过1次移植者TA-TMA风险高三倍。
  • aGVHD III-IV度者TA-TMA发生率显著高于aGVHD 0-II度者。

关键数值与推荐

  • 多因素分析中,活动性合并症、超过1次移植、aGVHD III-IV度的OR分别为5.1、5.2、26.9。
  • 以环孢素A/他克莫司为基础的GVHD预防不是TA-TMA的危险因素(OR:0.3)。
  • 性别、基础疾病、预处理强度、基于全身照射的预处理、钙调神经磷酸酶抑制剂的使用、静脉闭塞病和病毒再激活不影响TA-TMA的发生。

临床怎么用

  • 作者认为TA-TMA可能代表一种血管性GVHD,因此持续控制aGVHD对预防与GVHD相关的TA-TMA恶化很重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study aimed to identify a risk profile for development of transplant-associated thrombotic microangiopathy (TA-TMA) in children undergoing hematopoietic stem cell transplantation (HSCT). Between 2013 and 2016, 439 children underwent 474 HSCTs at 2 supraregional United Kingdom centers. At a median of 153 days post-HSCT, TA-TMA occurred among 25 of 441 evaluable cases (5.6%) with no evidence of center variation. Sex, underlying disease, intensity of the conditioning, total body irradiation-based conditioning, the use of calcineurin inhibitors, venoocclusive disease, and viral reactivation did not influence the development of TA-TMA. Donor type: matched sibling donor/matched family donor vs matched unrelated donor vs mismatched unrelated donor/haplo-HSCT, showed a trend toward the development of TA-TMA in 1.8% vs 6.1% vs 8.3%, respectively. Presence of active comorbidity was associated with an increased risk for TA-TMA; 13% vs 3.7% in the absence of comorbidity. The risk of TA-TMA was threefold higher among patients who received >1 transplant. TA-TMA rates were significantly higher among patients with acute graft-versus-host disease (aGVHD) grades III to IV vs aGVHD grade 0 to II. On multivariate analysis, the presence of active comorbidity, >1 transplant, aGVHD grade III to IV were risk factors for TA-TMA (odds ratio [OR]: 5.1, 5.2, and 26.9; respectively), whereas the use of cyclosporine A/tacrolimus-based GVHD prophylaxis was not a risk factor for TA-TMA (OR: 0.3). Active comorbidity, subsequent transplant, and aGVHD grades III to IV were significant risk factors for TA-TMA. TA-TMA might represent a form of a vascular GVHD, and therefore, continuing control of aGVHD is important to prevent worsening of TA-TMA associated with GVHD.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Elfeky R, Lucchini G, Lum SH, et al. New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT. Blood Adv. 2020. PMID: 32492158. doi:10.1182/bloodadvances.2019001315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。